
The evolution of lung cancer from a uniformly lethal disease to an illness compatible with long-term survivorship has stimulated a quest for prognostic and predictive biomarkers beyond the anatomic extent of disease, as in the Tumor Node Metastasis (TNM) staging system. Biomarkers guide the triaging of patients into different treatment pathways, rapidly splintering lung cancer into subsets of disease with different biologic behavior...
Like
Save
Share